Trilaciclib
- Generic Name
- Trilaciclib
- Brand Names
- Cosela
- Drug Type
- Small Molecule
- Chemical Formula
- C24H30N8O
- CAS Number
- 1374743-00-6
- Unique Ingredient Identifier
- U6072DO9XG
- Background
Trilaciclib, or G1T28, is a CDK4 and CDK6 inhibitor, indicated to reduce the incidence of chemotherapy induced myelosuppression in patients before topotecan-containing or platinum and etoposide-containing chemotherapy for extensive stage small cell lung cancer. CDK4 and CDK6 inhibitors have been investigated since the mid 1990s for their use in tumorigenesis...
- Indication
Trilaciclib is indicated to reduce the incidence of chemotherapy induced myelosuppression in patients prior to receiving platinum and etoposide-containing or topotecan-containing chemotherapy regimens for extensive-stage small cell lung cancer.
- Associated Conditions
- Bone Marrow Suppression caused by Chemotherapy
- Associated Therapies
- -
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)
- Conditions
- Interventions
- First Posted Date
- 2016-12-01
- Last Posted Date
- 2022-03-23
- Lead Sponsor
- G1 Therapeutics, Inc.
- Target Recruit Count
- 102
- Registration Number
- NCT02978716
- Locations
- 🇺🇸
Florida Cancer Specialists, Fort Myers, Florida, United States
🇺🇸Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States
🇺🇸Virginia Cancer Specialists, PC, Fairfax, Virginia, United States
Trilaciclib (G1T28) in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2015-08-03
- Last Posted Date
- 2022-06-09
- Lead Sponsor
- G1 Therapeutics, Inc.
- Target Recruit Count
- 123
- Registration Number
- NCT02514447
- Locations
- 🇺🇸
Genesis Cancer Center, Hot Springs, Arkansas, United States
🇺🇸Highlands Oncology Group, Rogers, Arkansas, United States
🇺🇸Greenville Health System, Greenville, South Carolina, United States
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Etoposide and Carboplatin in Extensive Stage Small Cell Lung Cancer (SCLC)
- Conditions
- Interventions
- First Posted Date
- 2015-07-16
- Last Posted Date
- 2020-08-21
- Lead Sponsor
- G1 Therapeutics, Inc.
- Target Recruit Count
- 122
- Registration Number
- NCT02499770
- Locations
- 🇺🇸
Roswell Park, Buffalo, New York, United States
🇫🇷CHU de Rennes Hopital Pontchaillou, Rennes, France
🇺🇸Florida Cancer Specialists - South, Fort Myers, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.